**Table 14.2.2.1.12 Overall Survival - Kaplan Meier estimation - EEP set (N = 47)**



| | Cohort I Murlentamab N = 13 | Cohort II Murlentamab + Trifluridine/tipiracil | | |
|---|---|---|---|---|
| | | Cohort II N = 13 | Cohort II (Expansion) N=21 | Total N = 34 |
| N | 13 | 13 | 21 | 34 |
| Censor | 0 (0.0%) | 1 (7.7%) | 6 (28.6%) | 7 (20.6%) |
| Death | 13 (100.0%) | 12 (92.3%) | 15 (71.4%) | 27 (79.4%) |
| Median follow-up time [95% CI] (months) [a] | Not reached | 33.08 [NA - NA] | 15.31 [12.62 - 16.26] | 16.03 [14.13 - 33.08] |
| Median follow-up time for survivors (months) [b] | 5.88 | 10.41 | 11.07 | 11.06 |
| Time to event: | | | | |
| Q3 [95% CI] (months) | 8.11 [5.55 - 20.57] | 12.68 [9.00 - NA] | Not reached | 19.06 [11.27 - NA] |
| Median [95% CI] (months) | 5.88 [5.03 - 8.11] | 10.41 [3.98 - 12.68] | 11.07 [6.87 - 13.17] | 11.06 [7.26 - 12.42] |
| Q1 [95% CI] (months) | 5.19 [2.30 - 5.88] | 8.67 [3.12 - 10.41] | 6.87 [2.14 - 7.49] | 6.87 [3.68 - 8.87] |
| Min ; Max | 2.30 ; 20.57 | 3.12 ; 33.08 | 2.14 ; 16.26 | 2.14 ; 33.08 |

[a] Reverse Kaplan-Meier estimation
[b] Calculated using observed follow-up time of survivors
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit

**Table 14.2.2.1.12 Overall Survival - Kaplan Meier estimation - EEP set (N = 47)**



| | Cohort I Murlentamab N = 13 | Cohort II Murlentamab + Trifluridine/tipiracil | | |
|---|---|---|---|---|
| | | Cohort II N = 13 | Cohort II (Expansion) N=21 | Total N = 34 |
| Survival rate at 2 months [95% CI] (%) | 100.00 [100.00 ; 100.00] | 100.00 [100.00 ; 100.00] | 100.00 [100.00 ; 100.00] | 100.00 [100.00 ; 100.00] |
| Survival rate at 4 months [95% CI] (%) | 84.60 [51.20 ; 96.00] | 77.00 [44.20 ; 92.00] | 90.40 [67.00 ; 97.60] | 85.20 [68.20 ; 93.60] |
| Survival rate at 6 months [95% CI] (%) | 38.40 [14.00 ; 62.80] | 77.00 [44.20 ; 92.00] | 76.20 [52.00 ; 89.40] | 76.40 [58.40 ; 87.40] |
| Survival rate at 8 months [95% CI] (%) | 30.80 [9.40 ; 55.40] | 77.00 [44.20 ; 92.00] | 57.20 [33.80 ; 75.00] | 64.80 [46.40 ; 78.20] |
| Survival rate at 10 months [95% CI] (%) | 23.00 [5.60 ; 47.40] | 53.80 [24.80 ; 76.00] | 57.20 [33.80 ; 75.00] | 55.80 [37.80 ; 70.60] |
| Survival rate at 12 months [95% CI] (%) | 7.60 [0.40 ; 29.20] | 30.80 [9.40 ; 55.40] | 38.00 [18.40 ; 57.80] | 35.20 [20.00 ; 51.00] |
| Survival rate at 14 months [95% CI] (%) | 7.60 [0.40 ; 29.20] | 23.00 [5.60 ; 47.40] | 27.80 [10.80 ; 47.80] | 25.80 [12.60 ; 41.40] |
| Survival rate at 16 months [95% CI] (%) | 7.60 [0.40 ; 29.20] | 23.00 [5.60 ; 47.40] | 27.80 [10.80 ; 47.80] | 25.80 [12.60 ; 41.40] |
| Survival rate at 18 months [95% CI] (%) | 7.60 [0.40 ; 29.20] | 23.00 [5.60 ; 47.40] | 27.80 [10.80 ; 47.80] | 25.80 [12.60 ; 41.40] |
| Survival rate at 20 months [95% CI] (%) | 7.60 [0.40 ; 29.20] | 15.40 [2.40 ; 38.80] | 27.80 [10.80 ; 47.80] | 17.20 [4.60 ; 36.60] |
| Survival rate at 22 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 15.40 [2.40 ; 38.80] | 27.80 [10.80 ; 47.80] | 17.20 [4.60 ; 36.60] |
| Survival rate at 24 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 7.60 [0.40 ; 29.20] | 27.80 [10.80 ; 47.80] | 8.60 [0.80 ; 29.40] |
| Survival rate at 26 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 7.60 [0.40 ; 29.20] | 27.80 [10.80 ; 47.80] | 8.60 [0.80 ; 29.40] |
| Survival rate at 28 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 7.60 [0.40 ; 29.20] | 27.80 [10.80 ; 47.80] | 8.60 [0.80 ; 29.40] |
| Survival rate at 30 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 7.60 [0.40 ; 29.20] | 27.80 [10.80 ; 47.80] | 8.60 [0.80 ; 29.40] |
| Survival rate at 32 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 7.60 [0.40 ; 29.20] | 27.80 [10.80 ; 47.80] | 8.60 [0.80 ; 29.40] |
| Survival rate at 34 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 7.60 [0.40 ; 29.20] | 27.80 [10.80 ; 47.80] | 8.60 [0.80 ; 29.40] |
| Survival rate at 36 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 7.60 [0.40 ; 29.20] | 27.80 [10.80 ; 47.80] | 8.60 [0.80 ; 29.40] |

[a] Reverse Kaplan-Meier estimation
[b] Calculated using observed follow-up time of survivors
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit

**Table 14.2.2.1.13 Overall Survival - Summary of events and censors over time - EEP set (N = 47)**



| | | 2 months | 4 months | 6 months | 8 months | 10 months | 12 months | 14 months | 16 months | 18 months | 20 months | 22 months | 24 months | 26 months | 28 months | 30 months |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Cohort I** | Events (n, %) | 0 (0%) | 2 (15.4%) | 8 (61.5%) | 9 (69.2%) | 10 (76.9%) | 12 (92.3%) | 12 (92.3%) | 12 (92.3%) | 12 (92.3%) | 12 (92.3%) | 13 (100%) | 13 (100%) | 13 (100%) | 13 (100%) | 13 (100%) |
| | Censors (n, %) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| | At-risk patients (n, %) | 13 (100%) | 11 (84.6%) | 5 (38.5%) | 4 (30.8%) | 3 (23.1%) | 1 (7.7%) | 1 (7.7%) | 1 (7.7%) | 1 (7.7%) | 1 (7.7%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| **Cohort II** | Events (n, %) | 0 (0%) | 3 (23.1%) | 3 (23.1%) | 3 (23.1%) | 6 (46.2%) | 9 (69.2%) | 10 (76.9%) | 10 (76.9%) | 10 (76.9%) | 11 (84.6%) | 11 (84.6%) | 12 (92.3%) | 12 (92.3%) | 12 (92.3%) | 12 (92.3%) |
| | Censors (n, %) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| | At-risk patients (n, %) | 13 (100%) | 10 (76.9%) | 10 (76.9%) | 10 (76.9%) | 7 (53.8%) | 4 (30.8%) | 3 (23.1%) | 3 (23.1%) | 3 (23.1%) | 2 (15.4%) | 2 (15.4%) | 1 (7.7%) | 1 (7.7%) | 1 (7.7%) | 1 (7.7%) |
| **Cohort II (Expansion)** | Events (n, %) | 0 (0%) | 2 (9.5%) | 5 (23.8%) | 9 (42.9%) | 9 (42.9%) | 13 (61.9%) | 15 (71.4%) | 15 (71.4%) | 15 (71.4%) | 15 (71.4%) | 15 (71.4%) | 15 (71.4%) | 15 (71.4%) | 15 (71.4%) | 15 (71.4%) |
| | Censors (n, %) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4.8%) | 4 (19%) | 6 (28.6%) | 6 (28.6%) | 6 (28.6%) | 6 (28.6%) | 6 (28.6%) | 6 (28.6%) | 6 (28.6%) |
| | At-risk patients (n, %) | 21 (100%) | 19 (90.5%) | 16 (76.2%) | 12 (57.1%) | 12 (57.1%) | 8 (38.1%) | 5 (23.8%) | 2 (9.5%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| **Total Cohort II** | Events (n, %) | 0 (0%) | 5 (14.7%) | 8 (23.5%) | 12 (35.3%) | 15 (44.1%) | 22 (64.7%) | 25 (73.5%) | 25 (73.5%) | 25 (73.5%) | 26 (76.5%) | 26 (76.5%) | 27 (79.4%) | 27 (79.4%) | 27 (79.4%) | 27 (79.4%) |
| | Censors (n, %) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (2.9%) | 4 (11.8%) | 6 (17.6%) | 6 (17.6%) | 6 (17.6%) | 6 (17.6%) | 6 (17.6%) | 6 (17.6%) | 6 (17.6%) |
| | At-risk patients (n, %) | 34 (100%) | 29 (85.3%) | 26 (76.5%) | 22 (64.7%) | 19 (55.9%) | 12 (35.3%) | 8 (23.5%) | 5 (14.7%) | 3 (8.8%) | 2 (5.9%) | 2 (5.9%) | 1 (2.9%) | 1 (2.9%) | 1 (2.9%) | 1 (2.9%) |

Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit

**Table 14.2.2.1.13 Overall Survival - Summary of events and censors over time - EEP set (N = 47)**



| | | 32 months | 34 months | 36 months |
|---|---|---|---|---|
| **Cohort I** | Events (n, %) | 13 (100%) | 13 (100%) | 13 (100%) |
| | Censors (n, %) | 0 (0%) | 0 (0%) | 0 (0%) |
| | At-risk patients (n, %) | 0 (0%) | 0 (0%) | 0 (0%) |
| **Cohort II** | Events (n, %) | 12 (92.3%) | 12 (92.3%) | 12 (92.3%) |
| | Censors (n, %) | 0 (0%) | 1 (7.7%) | 1 (7.7%) |
| | At-risk patients (n, %) | 1 (7.7%) | 0 (0%) | 0 (0%) |
| **Cohort II (Expansion)** | Events (n, %) | 15 (71.4%) | 15 (71.4%) | 15 (71.4%) |
| | Censors (n, %) | 6 (28.6%) | 6 (28.6%) | 6 (28.6%) |
| | At-risk patients (n, %) | 0 (0%) | 0 (0%) | 0 (0%) |
| **Total Cohort II** | Events (n, %) | 27 (79.4%) | 27 (79.4%) | 27 (79.4%) |
| | Censors (n, %) | 6 (17.6%) | 7 (20.6%) | 7 (20.6%) |
| | At-risk patients (n, %) | 1 (2.9%) | 0 (0%) | 0 (0%) |

Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit

**Figure 14.2.2.1.10: Kaplan Meier curve for Overall Survival: Cohort I - EEP set (N = 47)**




Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit

**Figure 14.2.2.1.11: Kaplan Meier curve for Overall Survival: Cohort II - EEP set (N = 47)**




Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit
p-value for Logrank test is 0.9773

**Table 14.2.2.1.26 Overall Survival - Kaplan Meier estimation - mITT set (N = 65)**



| | | Cohort II Murlentamab + Trifluridine/tipiracil | | |
|---|---|---|---|---|
| | **Cohort I Murlentamab N = 21** | **Cohort II N = 18** | **Cohort II expansion N = 26** | **Total N = 44** |
| N | 21 | 18 | 26 | 44 |
| Censor | 0 (0.0%) | 1 (5.6%) | 6 (23.1%) | 7 (15.9%) |
| Death | 21 (100.0%) | 17 (94.4%) | 20 (76.9%) | 37 (84.1%) |
| Median follow-up time [95% CI] (months) [a] | Not reached | 33.08 [NA - NA] | 15.31 [12.62 - 16.26] | 16.03 [14.13 - 33.08] |
| Median follow-up time for survivors (months) [b] | 5.29 | 8.94 | 7.38 | 8.77 |
| Time to event: | | | | |
| Q3 [95% CI] (months) | 7.26 [5.55 - 11.27] | 11.76 [9.00 - 22.37] | 13.17 [11.04 - NA] | 12.55 [11.07 - 22.37] |
| Median [95% CI] (months) | 5.29 [3.22 - 5.88] | 8.94 [3.42 - 11.37] | 7.38 [4.24 - 11.47] | 8.77 [5.62 - 11.27] |
| Q1 [95% CI] (months) | 3.22 [1.15 - 5.03] | 3.42 [1.05 - 8.67] | 3.98 [1.74 - 6.87] | 3.83 [1.74 - 6.87] |
| Min ; Max | 1.15 ; 20.57 | 1.05 ; 33.08 | 1.18 ; 16.26 | 1.05 ; 33.08 |

[a] Reverse Kaplan-Meier estimation
[b] Calculated using observed follow-up time of survivors
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit

**Table 14.2.2.1.26 Overall Survival - Kaplan Meier estimation - mITT set (N = 65)**



| | Cohort I Murlentamab N = 21 | Cohort II Murlentamab + Trifluridine/tipiracil | | |
|---|---|---|---|---|
| | | Cohort II N = 18 | Cohort II expansion N = 26 | Total N = 44 |
| Survival rate at 2 months [95% CI] (%) | 90.40 [67.00 ; 97.60] | 83.40 [56.80 ; 94.20] | 92.40 [72.60 ; 98.00] | 88.60 [74.80 ; 95.20] |
| Survival rate at 4 months [95% CI] (%) | 62.00 [38.00 ; 78.80] | 66.60 [40.40 ; 83.40] | 73.00 [51.60 ; 86.20] | 70.40 [54.60 ; 81.60] |
| Survival rate at 6 months [95% CI] (%) | 28.60 [11.60 ; 48.20] | 66.60 [40.40 ; 83.40] | 61.60 [40.40 ; 77.20] | 63.60 [47.60 ; 76.00] |
| Survival rate at 8 months [95% CI] (%) | 19.00 [6.00 ; 37.80] | 61.20 [35.40 ; 79.20] | 46.20 [26.60 ; 63.60] | 52.20 [36.60 ; 65.80] |
| Survival rate at 10 months [95% CI] (%) | 14.20 [3.60 ; 32.20] | 44.40 [21.60 ; 65.20] | 46.20 [26.60 ; 63.60] | 45.40 [30.40 ; 59.20] |
| Survival rate at 12 months [95% CI] (%) | 4.80 [0.40 ; 19.80] | 22.20 [7.00 ; 42.80] | 30.80 [14.60 ; 48.60] | 27.20 [15.20 ; 40.80] |
| Survival rate at 14 months [95% CI] (%) | 4.80 [0.40 ; 19.80] | 16.60 [4.20 ; 36.60] | 22.40 [8.80 ; 40.00] | 20.00 [9.60 ; 33.00] |
| Survival rate at 16 months [95% CI] (%) | 4.80 [0.40 ; 19.80] | 16.60 [4.20 ; 36.60] | 22.40 [8.80 ; 40.00] | 20.00 [9.60 ; 33.00] |
| Survival rate at 18 months [95% CI] (%) | 4.80 [0.40 ; 19.80] | 16.60 [4.20 ; 36.60] | 22.40 [8.80 ; 40.00] | 20.00 [9.60 ; 33.00] |
| Survival rate at 20 months [95% CI] (%) | 4.80 [0.40 ; 19.80] | 11.20 [1.80 ; 29.80] | 22.40 [8.80 ; 40.00] | 13.40 [3.60 ; 29.40] |
| Survival rate at 22 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 11.20 [1.80 ; 29.80] | 22.40 [8.80 ; 40.00] | 13.40 [3.60 ; 29.40] |
| Survival rate at 24 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 5.60 [0.40 ; 22.40] | 22.40 [8.80 ; 40.00] | 6.60 [0.60 ; 23.60] |
| Survival rate at 26 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 5.60 [0.40 ; 22.40] | 22.40 [8.80 ; 40.00] | 6.60 [0.60 ; 23.60] |
| Survival rate at 28 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 5.60 [0.40 ; 22.40] | 22.40 [8.80 ; 40.00] | 6.60 [0.60 ; 23.60] |
| Survival rate at 30 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 5.60 [0.40 ; 22.40] | 22.40 [8.80 ; 40.00] | 6.60 [0.60 ; 23.60] |
| Survival rate at 32 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 5.60 [0.40 ; 22.40] | 22.40 [8.80 ; 40.00] | 6.60 [0.60 ; 23.60] |
| Survival rate at 34 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 5.60 [0.40 ; 22.40] | 22.40 [8.80 ; 40.00] | 6.60 [0.60 ; 23.60] |
| Survival rate at 36 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 5.60 [0.40 ; 22.40] | 22.40 [8.80 ; 40.00] | 6.60 [0.60 ; 23.60] |

[a] Reverse Kaplan-Meier estimation
[b] Calculated using observed follow-up time of survivors
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit

**Table 14.2.2.1.27 Overall Survival - Summary of events and censors over time - mITT set (N = 65)**



| | | 2 months | 4 months | 6 months | 8 months | 10 months | 12 months | 14 months | 16 months | 18 months |
|---|---|---|---|---|---|---|---|---|---|---|
| **Cohort I** | Events (n, %) | 2 (9.5%) | 8 (38.1%) | 15 (71.4%) | 17 (81%) | 18 (85.7%) | 20 (95.2%) | 20 (95.2%) | 20 (95.2%) | 20 (95.2%) |
| | Censors (n, %) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| | At-risk patients (n, %) | 19 (90.5%) | 13 (61.9%) | 6 (28.6%) | 4 (19%) | 3 (14.3%) | 1 (4.8%) | 1 (4.8%) | 1 (4.8%) | 1 (4.8%) |
| **Cohort II** | Events (n, %) | 3 (16.7%) | 6 (33.3%) | 6 (33.3%) | 7 (38.9%) | 10 (55.6%) | 14 (77.8%) | 15 (83.3%) | 15 (83.3%) | 15 (83.3%) |
| | Censors (n, %) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| | At-risk patients (n, %) | 15 (83.3%) | 12 (66.7%) | 12 (66.7%) | 11 (61.1%) | 8 (44.4%) | 4 (22.2%) | 3 (16.7%) | 3 (16.7%) | 3 (16.7%) |
| **Cohort II (Expansion)** | Events (n, %) | 2 (7.7%) | 7 (26.9%) | 10 (38.5%) | 14 (53.8%) | 14 (53.8%) | 18 (69.2%) | 20 (76.9%) | 20 (76.9%) | 20 (76.9%) |
| | Censors (n, %) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (3.8%) | 4 (15.4%) | 6 (23.1%) |
| | At-risk patients (n, %) | 24 (92.3%) | 19 (73.1%) | 16 (61.5%) | 12 (46.2%) | 12 (46.2%) | 8 (30.8%) | 5 (19.2%) | 2 (7.7%) | 0 (0%) |
| **Total Cohort II** | Events (n, %) | 5 (11.4%) | 13 (29.5%) | 16 (36.4%) | 21 (47.7%) | 24 (54.5%) | 32 (72.7%) | 35 (79.5%) | 35 (79.5%) | 35 (79.5%) |
| | Censors (n, %) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (2.3%) | 4 (9.1%) | 6 (13.6%) |
| | At-risk patients (n, %) | 39 (88.6%) | 31 (70.5%) | 28 (63.6%) | 23 (52.3%) | 20 (45.5%) | 12 (27.3%) | 8 (18.2%) | 5 (11.4%) | 3 (6.8%) |

Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit

**Table 14.2.2.1.27 Overall Survival - Summary of events and censors over time - mITT set (N = 65)**



| | | 20 months | 22 months | 24 months | 26 months | 28 months | 30 months | 32 months | 34 months | 36 months |
|---|---|---|---|---|---|---|---|---|---|---|
| **Cohort I** | Events (n, %) | 20 (95.2%) | 21 (100%) | 21 (100%) | 21 (100%) | 21 (100%) | 21 (100%) | 21 (100%) | 21 (100%) | 21 (100%) |
| | Censors (n, %) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| | At-risk patients (n, %) | 1 (4.8%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| **Cohort II** | Events (n, %) | 16 (88.9%) | 16 (88.9%) | 17 (94.4%) | 17 (94.4%) | 17 (94.4%) | 17 (94.4%) | 17 (94.4%) | 17 (94.4%) | 17 (94.4%) |
| | Censors (n, %) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (5.6%) | 1 (5.6%) |
| | At-risk patients (n, %) | 2 (11.1%) | 2 (11.1%) | 1 (5.6%) | 1 (5.6%) | 1 (5.6%) | 1 (5.6%) | 1 (5.6%) | 0 (0%) | 0 (0%) |
| **Cohort II (Expansion)** | Events (n, %) | 20 (76.9%) | 20 (76.9%) | 20 (76.9%) | 20 (76.9%) | 20 (76.9%) | 20 (76.9%) | 20 (76.9%) | 20 (76.9%) | 20 (76.9%) |
| | Censors (n, %) | 6 (23.1%) | 6 (23.1%) | 6 (23.1%) | 6 (23.1%) | 6 (23.1%) | 6 (23.1%) | 6 (23.1%) | 6 (23.1%) | 6 (23.1%) |
| | At-risk patients (n, %) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| **Total Cohort II** | Events (n, %) | 36 (81.8%) | 36 (81.8%) | 37 (84.1%) | 37 (84.1%) | 37 (84.1%) | 37 (84.1%) | 37 (84.1%) | 37 (84.1%) | 37 (84.1%) |
| | Censors (n, %) | 6 (13.6%) | 6 (13.6%) | 6 (13.6%) | 6 (13.6%) | 6 (13.6%) | 6 (13.6%) | 6 (13.6%) | 7 (15.9%) | 7 (15.9%) |
| | At-risk patients (n, %) | 2 (4.5%) | 2 (4.5%) | 1 (2.3%) | 1 (2.3%) | 1 (2.3%) | 1 (2.3%) | 1 (2.3%) | 0 (0%) | 0 (0%) |

Patients who didn’t experienced the analysis event and still under study follow-up have been censored at the time of the last available visit

**Figure 14.2.2.1.21: Kaplan Meier curve for Overall Survival: Cohort I - mITT set (N = 65)**




Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit

**Figure 14.2.2.1.22: Kaplan Meier curve for Overall Survival: Cohort II - mITT set (N = 65)**




Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit
p-value for Logrank test is 0.9493

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS.sas

**Table 14.2.2.2.12 Overall Survival - Kaplan Meier estimation - EEP set (N = 47)**



| | Cohort I Murlentamab | | Cohort II Murlentamab + Trifluridine/tipiracil | |
|---|---|---|---|---|
| | **AMHRII membrane expression < 20% N = 6** | **AMHRII membrane expression ≥ 20% N = 3** | **AMHRII membrane expression < 20% N = 17** | **AMHRII membrane expression ≥ 20% N = 13** |
| N | 6 | 3 | 17 | 13 |
| Censor | 0 (0.0%) | 0 (0.0%) | 3 (17.6%) | 3 (23.1%) |
| Death | 6 (100.0%) | 3 (100.0%) | 14 (82.4%) | 10 (76.9%) |
| Median follow-up time [95% CI] (months) [a] | Not reached | Not reached | 15.20 [12.62 - NA] | 24.56 [15.31 - 33.08] |
| Median follow-up time for survivors (months) [b] | 6.60 | 5.88 | 9.00 | 11.76 |
| Time to event: | | | | |
| Q3 [95% CI] (months) | 10.48 [3.38 - 20.57] | 8.11 [5.03 - 8.11] | 11.47 [9.00 - 19.06] | 22.37 [11.04 - NA] |
| Median [95% CI] (months) | 6.60 [2.30 - 20.57] | 5.88 [5.03 - 8.11] | 9.00 [3.68 - 11.47] | 11.76 [7.13 - 22.37] |
| Q1 [95% CI] (months) | 3.38 [2.30 - 7.66] | 5.03 [5.03 - 8.11] | 3.98 [2.14 - 8.87] | 7.49 [5.62 - 11.76] |
| Min ; Max | 2.30 ; 20.57 | 5.03 ; 8.11 | 2.14 ; 19.06 | 5.62 ; 33.08 |

[a] Reverse Kaplan-Meier estimation
[b] Calculated using observed follow-up time of survivors
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit

**Table 14.2.2.2.12 Overall Survival - Kaplan Meier estimation - EEP set (N = 47)**



| | Cohort I Murlentamab | | Cohort II Murlentamab + Trifluridine/tipiracil | |
|---|---|---|---|---|
| | **AMHRII membrane expression < 20% N = 6** | **AMHRII membrane expression ≥ 20% N = 3** | **AMHRII membrane expression < 20% N = 17** | **AMHRII membrane expression ≥ 20% N = 13** |
| Survival rate at 2 months [95% CI] (%) | 100.00 [100.00 ; 100.00] | 100.00 [100.00 ; 100.00] | 100.00 [100.00 ; 100.00] | 100.00 [100.00 ; 100.00] |
| Survival rate at 4 months [95% CI] (%) | 66.60 [19.40 ; 90.40] | 100.00 [100.00 ; 100.00] | 70.60 [43.20 ; 86.60] | 100.00 [100.00 ; 100.00] |
| Survival rate at 6 months [95% CI] (%) | 50.00 [11.00 ; 80.40] | 33.40 [0.80 ; 77.40] | 64.80 [37.80 ; 82.40] | 84.60 [51.20 ; 96.00] |
| Survival rate at 8 months [95% CI] (%) | 33.40 [4.60 ; 67.60] | 33.40 [0.80 ; 77.40] | 58.80 [32.60 ; 77.80] | 69.20 [37.40 ; 87.20] |
| Survival rate at 10 months [95% CI] (%) | 33.40 [4.60 ; 67.60] | 0.00 [0.00 ; 0.00] | 47.00 [23.00 ; 68.00] | 61.60 [30.80 ; 81.80] |
| Survival rate at 12 months [95% CI] (%) | 16.60 [0.80 ; 51.60] | 0.00 [0.00 ; 0.00] | 23.60 [7.40 ; 45.00] | 46.20 [19.20 ; 69.60] |
| Survival rate at 14 months [95% CI] (%) | 16.60 [0.80 ; 51.60] | 0.00 [0.00 ; 0.00] | 23.60 [7.40 ; 45.00] | 30.80 [9.40 ; 55.40] |
| Survival rate at 16 months [95% CI] (%) | 16.60 [0.80 ; 51.60] | 0.00 [0.00 ; 0.00] | 23.60 [7.40 ; 45.00] | 30.80 [9.40 ; 55.40] |
| Survival rate at 18 months [95% CI] (%) | 16.60 [0.80 ; 51.60] | 0.00 [0.00 ; 0.00] | 23.60 [7.40 ; 45.00] | 30.80 [9.40 ; 55.40] |
| Survival rate at 20 months [95% CI] (%) | 16.60 [0.80 ; 51.60] | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 30.80 [9.40 ; 55.40] |
| Survival rate at 22 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 30.80 [9.40 ; 55.40] |
| Survival rate at 24 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 15.40 [1.20 ; 45.20] |
| Survival rate at 26 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 15.40 [1.20 ; 45.20] |
| Survival rate at 28 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 15.40 [1.20 ; 45.20] |
| Survival rate at 30 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 15.40 [1.20 ; 45.20] |
| Survival rate at 32 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 15.40 [1.20 ; 45.20] |
| Survival rate at 34 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 15.40 [1.20 ; 45.20] |
| Survival rate at 36 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 15.40 [1.20 ; 45.20] |
| Hazard ratio [95% CI, 2-sided] | | | | 1.764 [ 0.756 - 4.116 ] |

[a] Reverse Kaplan-Meier estimation
[b] Calculated using observed follow-up time of survivors
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit

**Table 14.2.2.2.13 Overall Survival - Summary of events and censors over time - EEP set (N = 47)**



| | | 2 months | 4 months | 6 months | 8 months | 10 months | 12 months | 14 months | 16 months | 18 months |
|---|---|---|---|---|---|---|---|---|---|---|
| **C1 - AMHRII < 20%** | Events (n, %) | 0 (0%) | 2 (33.3%) | 3 (50%) | 4 (66.7%) | 4 (66.7%) | 5 (83.3%) | 5 (83.3%) | 5 (83.3%) | 5 (83.3%) |
| | Censors (n, %) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| | At-risk patients (n, %) | 6 (100%) | 4 (66.7%) | 3 (50%) | 2 (33.3%) | 2 (33.3%) | 1 (16.7%) | 1 (16.7%) | 1 (16.7%) | 1 (16.7%) |
| **C1 - AMHRII >= 20%** | Events (n, %) | 0 (0%) | 0 (0%) | 2 (66.7%) | 2 (66.7%) | 3 (100%) | 3 (100%) | 3 (100%) | 3 (100%) | 3 (100%) |
| | Censors (n, %) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| | At-risk patients (n, %) | 3 (100%) | 3 (100%) | 1 (33.3%) | 1 (33.3%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| **C2 - AMHRII < 20%** | Events (n, %) | 0 (0%) | 5 (29.4%) | 6 (35.3%) | 7 (41.2%) | 9 (52.9%) | 13 (76.5%) | 13 (76.5%) | 13 (76.5%) | 13 (76.5%) |
| | Censors (n, %) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (5.9%) | 2 (11.8%) | 3 (17.6%) |
| | At-risk patients (n, %) | 17 (100%) | 12 (70.6%) | 11 (64.7%) | 10 (58.8%) | 8 (47.1%) | 4 (23.5%) | 3 (17.6%) | 2 (11.8%) | 1 (5.9%) |
| **C2 - AMHRII >= 20%** | Events (n, %) | 0 (0%) | 0 (0%) | 2 (15.4%) | 4 (30.8%) | 5 (38.5%) | 7 (53.8%) | 9 (69.2%) | 9 (69.2%) | 9 (69.2%) |
| | Censors (n, %) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (7.7%) | 2 (15.4%) |
| | At-risk patients (n, %) | 13 (100%) | 13 (100%) | 11 (84.6%) | 9 (69.2%) | 8 (61.5%) | 6 (46.2%) | 4 (30.8%) | 3 (23.1%) | 2 (15.4%) |

Patients who didn’t experienced the analysis event and still under study follow-up have been censored at the time of the last available visit

**Table 14.2.2.2.13 Overall Survival - Summary of events and censors over time - EEP set (N = 47)**



| | | 20 months | 22 months | 24 months | 26 months | 28 months | 30 months | 32 months | 34 months | 36 months |
|---|---|---|---|---|---|---|---|---|---|---|
| **C1 - AMHRII < 20%** | Events (n, %) | 5 (83.3%) | 6 (100%) | 6 (100%) | 6 (100%) | 6 (100%) | 6 (100%) | 6 (100%) | 6 (100%) | 6 (100%) |
| | Censors (n, %) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| | At-risk patients (n, %) | 1 (16.7%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| **C1 - AMHRII >= 20%** | Events (n, %) | 3 (100%) | 3 (100%) | 3 (100%) | 3 (100%) | 3 (100%) | 3 (100%) | 3 (100%) | 3 (100%) | 3 (100%) |
| | Censors (n, %) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| | At-risk patients (n, %) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| **C2 - AMHRII < 20%** | Events (n, %) | 14 (82.4%) | 14 (82.4%) | 14 (82.4%) | 14 (82.4%) | 14 (82.4%) | 14 (82.4%) | 14 (82.4%) | 14 (82.4%) | 14 (82.4%) |
| | Censors (n, %) | 3 (17.6%) | 3 (17.6%) | 3 (17.6%) | 3 (17.6%) | 3 (17.6%) | 3 (17.6%) | 3 (17.6%) | 3 (17.6%) | 3 (17.6%) |
| | At-risk patients (n, %) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| **C2 - AMHRII >= 20%** | Events (n, %) | 9 (69.2%) | 9 (69.2%) | 10 (76.9%) | 10 (76.9%) | 10 (76.9%) | 10 (76.9%) | 10 (76.9%) | 10 (76.9%) | 10 (76.9%) |
| | Censors (n, %) | 2 (15.4%) | 2 (15.4%) | 2 (15.4%) | 2 (15.4%) | 2 (15.4%) | 2 (15.4%) | 2 (15.4%) | 3 (23.1%) | 3 (23.1%) |
| | At-risk patients (n, %) | 2 (15.4%) | 2 (15.4%) | 1 (7.7%) | 1 (7.7%) | 1 (7.7%) | 1 (7.7%) | 1 (7.7%) | 0 (0%) | 0 (0%) |

Patients who didn’t experienced the analysis event and still under study follow-up have been censored at the time of the last available visit

**Figure 14.2.2.2.10: Kaplan Meier curve for Overall Survival: Cohort I - EEP set (N = 47)**




Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit
p-value for Logrank test is 0.6631

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS_AMHRII.sas

**Figure 14.2.2.2.11: Kaplan Meier curve for Overall Survival: Cohort II - EEP set (N = 47)**




Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit
p-value for Logrank test is 0.2133

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS_AMHRII.sas

**Table 14.2.2.2.26 Overall Survival - Kaplan Meier estimation - mITT set (N = 65)**



| | Cohort I Murlentamab | | Cohort II Murlentamab + Trifluridine/tipiracil | |
|---|---|---|---|---|
| | **AMHRII membrane expression < 20% N = 12** | **AMHRII membrane expression ≥ 20% N = 4** | **AMHRII membrane expression < 20% N = 24** | **AMHRII membrane expression ≥ 20% N = 16** |
| N | 12 | 4 | 24 | 16 |
| Censor | 0 (0.0%) | 0 (0.0%) | 3 (12.5%) | 3 (18.8%) |
| Death | 12 (100.0%) | 4 (100.0%) | 21 (87.5%) | 13 (81.3%) |
| Median follow-up time [95% CI] (months) [a] | Not reached | Not reached | 15.20 [12.62 - NA] | 24.56 [15.31 - 33.08] |
| Median follow-up time for survivors (months) [b] | 4.47 | 5.45 | 7.06 | 9.86 |
| Time to event: | | | | |
| Q3 [95% CI] (months) | 7.46 [3.38 - 20.57] | 7.00 [3.52 - 8.11] | 11.32 [8.87 - 19.06] | 17.53 [8.67 - NA] |
| Median [95% CI] (months) | 4.47 [1.77 - 7.66] | 5.45 [3.52 - 8.11] | 7.06 [3.42 - 11.07] | 9.86 [5.62 - 12.68] |
| Q1 [95% CI] (months) | 2.28 [1.15 - 3.38] | 4.27 [3.52 - 5.88] | 3.27 [1.05 - 3.98] | 5.80 [1.05 - 8.67] |
| Min ; Max | 1.15 ; 20.57 | 3.52 ; 8.11 | 1.05 ; 19.06 | 1.05 ; 33.08 |

[a] Reverse Kaplan-Meier estimation
[b] Calculated using observed follow-up time of survivors
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit

**Table 14.2.2.2.26 Overall Survival - Kaplan Meier estimation - mITT set (N = 65)**



| | Cohort I Murlentamab | | Cohort II Murlentamab + Trifluridine/tipiracil | |
|---|---|---|---|---|
| | AMHRII membrane expression < 20% N = 12 | AMHRII membrane expression ≥ 20% N = 4 | AMHRII membrane expression < 20% N = 24 | AMHRII membrane expression ≥ 20% N = 16 |
| Survival rate at 2 months [95% CI] (%) | 83.40 [48.20 ; 95.60] | 100.00 [100.00 ; 100.00] | 91.60 [70.60 ; 97.80] | 81.20 [52.40 ; 93.60] |
| Survival rate at 4 months [95% CI] (%) | 50.00 [20.80 ; 73.60] | 75.00 [12.80 ; 96.00] | 58.40 [36.40 ; 75.00] | 81.20 [52.40 ; 93.60] |
| Survival rate at 6 months [95% CI] (%) | 33.40 [10.20 ; 58.80] | 25.00 [0.80 ; 66.60] | 54.20 [32.80 ; 71.40] | 68.80 [40.40 ; 85.60] |
| Survival rate at 8 months [95% CI] (%) | 16.60 [2.60 ; 41.20] | 25.00 [0.80 ; 66.60] | 45.80 [25.60 ; 64.00] | 56.20 [29.60 ; 76.20] |
| Survival rate at 10 months [95% CI] (%) | 16.60 [2.60 ; 41.20] | 0.00 [0.00 ; 0.00] | 37.60 [19.00 ; 56.00] | 50.00 [24.60 ; 71.00] |
| Survival rate at 12 months [95% CI] (%) | 8.40 [0.60 ; 31.20] | 0.00 [0.00 ; 0.00] | 16.60 [5.20 ; 33.80] | 37.60 [15.40 ; 59.80] |
| Survival rate at 14 months [95% CI] (%) | 8.40 [0.60 ; 31.20] | 0.00 [0.00 ; 0.00] | 16.60 [5.20 ; 33.80] | 25.00 [7.80 ; 47.20] |
| Survival rate at 16 months [95% CI] (%) | 8.40 [0.60 ; 31.20] | 0.00 [0.00 ; 0.00] | 16.60 [5.20 ; 33.80] | 25.00 [7.80 ; 47.20] |
| Survival rate at 18 months [95% CI] (%) | 8.40 [0.60 ; 31.20] | 0.00 [0.00 ; 0.00] | 16.60 [5.20 ; 33.80] | 25.00 [7.80 ; 47.20] |
| Survival rate at 20 months [95% CI] (%) | 8.40 [0.60 ; 31.20] | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 25.00 [7.80 ; 47.20] |
| Survival rate at 22 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 25.00 [7.80 ; 47.20] |
| Survival rate at 24 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 12.60 [1.00 ; 38.60] |
| Survival rate at 26 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 12.60 [1.00 ; 38.60] |
| Survival rate at 28 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 12.60 [1.00 ; 38.60] |
| Survival rate at 30 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 12.60 [1.00 ; 38.60] |
| Survival rate at 32 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 12.60 [1.00 ; 38.60] |
| Survival rate at 34 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 12.60 [1.00 ; 38.60] |
| Survival rate at 36 months [95% CI] (%) | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 0.00 [0.00 ; 0.00] | 12.60 [1.00 ; 38.60] |
| Hazard ratio [95% CI, 2-sided] | | | | 1.610 [ 0.785 - 3.300 ] |

[a] Reverse Kaplan-Meier estimation
[b] Calculated using observed follow-up time of survivors
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit

**Table 14.2.2.2.27 Overall Survival - Summary of events and censors over time - mITT set (N = 65)**



| | | 2 months | 4 months | 6 months | 8 months | 10 months | 12 months | 14 months | 16 months | 18 months |
|---|---|---|---|---|---|---|---|---|---|---|
| **C1 - AMHRII < 20%** | Events (n, %) | 2 (16.7%) | 6 (50%) | 8 (66.7%) | 10 (83.3%) | 10 (83.3%) | 11 (91.7%) | 11 (91.7%) | 11 (91.7%) | 11 (91.7%) |
| | Censors (n, %) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| | At-risk patients (n, %) | 10 (83.3%) | 6 (50%) | 4 (33.3%) | 2 (16.7%) | 2 (16.7%) | 1 (8.3%) | 1 (8.3%) | 1 (8.3%) | 1 (8.3%) |
| **C1 - AMHRII >= 20%** | Events (n, %) | 0 (0%) | 1 (25%) | 3 (75%) | 3 (75%) | 4 (100%) | 4 (100%) | 4 (100%) | 4 (100%) | 4 (100%) |
| | Censors (n, %) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| | At-risk patients (n, %) | 4 (100%) | 3 (75%) | 1 (25%) | 1 (25%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| **C2 - AMHRII < 20%** | Events (n, %) | 2 (8.3%) | 10 (41.7%) | 11 (45.8%) | 13 (54.2%) | 15 (62.5%) | 20 (83.3%) | 20 (83.3%) | 20 (83.3%) | 20 (83.3%) |
| | Censors (n, %) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4.2%) | 2 (8.3%) | 3 (12.5%) |
| | At-risk patients (n, %) | 22 (91.7%) | 14 (58.3%) | 13 (54.2%) | 11 (45.8%) | 9 (37.5%) | 4 (16.7%) | 3 (12.5%) | 2 (8.3%) | 1 (4.2%) |
| **C2 - AMHRII >= 20%** | Events (n, %) | 3 (18.8%) | 3 (18.8%) | 5 (31.3%) | 7 (43.8%) | 8 (50%) | 10 (62.5%) | 12 (75%) | 12 (75%) | 12 (75%) |
| | Censors (n, %) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (6.3%) | 2 (12.5%) |
| | At-risk patients (n, %) | 13 (81.3%) | 13 (81.3%) | 11 (68.8%) | 9 (56.3%) | 8 (50%) | 6 (37.5%) | 4 (25%) | 3 (18.8%) | 2 (12.5%) |

Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit

**Table 14.2.2.2.27 Overall Survival - Summary of events and censors over time - mITT set (N = 65)**



| | | 20 months | 22 months | 24 months | 26 months | 28 months | 30 months | 32 months | 34 months | 36 months |
|---|---|---|---|---|---|---|---|---|---|---|
| **C1 - AMHRII < 20%** | Events (n, %) | 11 (91.7%) | 12 (100%) | 12 (100%) | 12 (100%) | 12 (100%) | 12 (100%) | 12 (100%) | 12 (100%) | 12 (100%) |
| | Censors (n, %) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| | At-risk patients (n, %) | 1 (8.3%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| **C1 - AMHRII >= 20%** | Events (n, %) | 4 (100%) | 4 (100%) | 4 (100%) | 4 (100%) | 4 (100%) | 4 (100%) | 4 (100%) | 4 (100%) | 4 (100%) |
| | Censors (n, %) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| | At-risk patients (n, %) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| **C2 - AMHRII < 20%** | Events (n, %) | 21 (87.5%) | 21 (87.5%) | 21 (87.5%) | 21 (87.5%) | 21 (87.5%) | 21 (87.5%) | 21 (87.5%) | 21 (87.5%) | 21 (87.5%) |
| | Censors (n, %) | 3 (12.5%) | 3 (12.5%) | 3 (12.5%) | 3 (12.5%) | 3 (12.5%) | 3 (12.5%) | 3 (12.5%) | 3 (12.5%) | 3 (12.5%) |
| | At-risk patients (n, %) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| **C2 - AMHRII >= 20%** | Events (n, %) | 12 (75%) | 12 (75%) | 13 (81.3%) | 13 (81.3%) | 13 (81.3%) | 13 (81.3%) | 13 (81.3%) | 13 (81.3%) | 13 (81.3%) |
| | Censors (n, %) | 2 (12.5%) | 2 (12.5%) | 2 (12.5%) | 2 (12.5%) | 2 (12.5%) | 2 (12.5%) | 2 (12.5%) | 3 (18.8%) | 3 (18.8%) |
| | At-risk patients (n, %) | 2 (12.5%) | 2 (12.5%) | 1 (6.3%) | 1 (6.3%) | 1 (6.3%) | 1 (6.3%) | 1 (6.3%) | 0 (0%) | 0 (0%) |

Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit

**Figure 14.2.2.2.21: Kaplan Meier curve for Overall Survival: Cohort I - mITT set (N = 65)**




Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit
p-value for Logrank test is 0.9099

**Figure 14.2.2.2.22: Kaplan Meier curve for Overall Survival: Cohort II - mITT set (N = 65)**




Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit
p-value for Logrank test is 0.2129

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS_AMHRII.sas